---
source: "2026 - Acute Impact of Cold Compression Therapy Across Diverse Age Groups and Physical Conditioning Status A Randomized Crossover Study - Trybulski et al.pdf"
folder: "/GSE-Research/sports-research-papers/library/journals/Journal of Sports Science and Medicine/2026"
pages: 21
model: nvidia/nemotron-3.5-super-vl-120b-a12b
words: 4650
---

<NATIVE_REASONING>
The user wants a deep reasoning analysis of the provided source paper (Trybulski et al., 2026, JSSM) on cold compression therapy across age groups and conditioning status. I need to follow strict invariants:

1. ZERO BETTING LINES: Never mention spreads, totals, moneylines, or odds.
2. ZERO TOY EQUATIONS: Never invent fake ratios (Force / Fatigue). State formal LaTeX equations, SI/information/probability units, assumptions, and exact singularity/breakdown regimes. When source pages are provided, cite exact [PAGE N] markers and verbatim quotes.
3. >= 1,000-WORD DEPTH across these exact XML sections:
   - <THINK_TRACE>Deep multi-hop derivation & gray-zone audit (>=400 words).</THINK_TRACE>
   - <SOURCE_OPERATORS_AND_EQUATIONS>Formal LaTeX, units, page citations, breakdown.</SOURCE_OPERATORS_AND_EQUATIONS>
   - <RETROCAUSAL_GENEALOGY>Historical/scientific lineage & multi-week traps.</RETROCAUSAL_GENEALOGY>
   - <RECURSIVE_THEORY_OF_MIND>Crisis habit regression vs counter-trap vs clock.</RECURSIVE_THEORY_OF_MIND>
   - <CROSS_LAYER_VETO_ADJUDICATION>Physical/biomechanical/weather veto proof.</CROSS_LAYER_VETO_ADJUDICATION>
   - <RLVR_COUNTERFACTUAL_VETOES>3 verifiable RLVR veto scenarios + predictions.</RLVR_COUNTERFACTUAL_VETOES>

I need to produce a comprehensive analysis with these exact XML sections. No betting lines. No fake ratios. Formal LaTeX equations with SI units. Page citations [PAGE N]. Verbatim quotes where possible.

Let me structure this carefully.

First, let me extract key data from the paper:

- Study: Trybulski et al. 2026, JSSM 24, 350-370. DOI: 10.52082/jssm.2026.350.
- Multicenter, randomized, participant- and assessor-blinded, sham-controlled, two-period crossover trial.
- N=80 participants: 40 elite MMA athletes, 20 young adults (20-24 years), 20 older adults (>50 years).
- Intervention: CC (3 °C, 75 mmHg, 10 min twice daily for 3 days) vs Sham (15 °C, 15 mmHg).
- Fatigue protocol: Nordic Hamstring Exercise (NHE) to volitional exhaustion, 3 sets, 2 min rest.
- Outcomes: MVC (primary), muscle stiffness, microvascular perfusion, PPT, blood lactate, TQR, Borg CR10, harms.
- Timepoints: T0 baseline, T1 post-fatigue, T2 immediately post-first intervention, T3 24h, T4 48h.
- Statistical: mixed-way ANOVA (3-way: Population × Condition × Time), Bonferroni, Cohen's dz.
- Sample size: a priori target n=117 (dz=0.30, α=0.05, 90% power), achieved n=80 (pragmatic cap). Post hoc power >99% for observed dz=1.0 at T4.

Key results:
- MVC: CC > Sham from T2 to T4 (all p < .001). Largest difference at T4 (+95.4 N pooled). dz = 0.76 at T2, 0.97 at T3, 1.02 at T4. Population effect F(2,77)=129.26, p<.001, ηp²=.771. At T4: MMA 96.1% vs 87.7%; Young 76.3% vs 61.1%; Older 69.1% vs 46.2% (CC vs Sham % of baseline). Onset: T2 in MMA/young, T3 in older.
- Stiffness: CC < Sham from T2 to T4 (all p<.001). dz = -3.54 at T2, -2.29 at T3, -2.50 at T4. Pooled mean differences: -21.7, -9.0, -26.3 N/m. At T4 stiffness above baseline: CC 18.0% (MMA/young) and 32.1% (older); Sham 50.6%, 61.0%, 62.5%.
- Perfusion: CC > Sham at T2-T4. +6.807 PU at T2, +0.897 PU at T3, +1.093 PU at T4; dz=2.14, 0.83, 0.82. Population main effect F(2,77)=280.91, p<.001, ηp²=.879. Onset: T2 MMA/young, T3 older.
- PPT: CC > Sham from T2 onward. +3.408 N/cm² at T2, +3.296 N/cm² at T3, +15.018 N/cm² at T4; dz=0.55, 0.46, 1.88. Population main effect F(2,77)=313.80, p<.001, ηp²=.891.
- Blood lactate: lower under CC only at T2 (-1.125 mmol/L, dz=-3.49, p<.001). No diff at T0, T1, T3, T4.
- TQR: CC higher at T2-T4 in MMA, T2-T3 in older, T3 only in young.
- Borg CR10: no between-condition diff. OR=19.44 older vs MMA, OR=8.10 young vs MMA.
- Harms: No adverse events.

Limitations:
- Sample smaller than a priori target (80 vs 117), unequal subgroups (40/20/20).
- Did not measure skin/intramuscular temperatures or real-time cuff pressures.
- No direct biochemical markers of inflammation, shear-wave elastography, MRI.
- Single commercial device, fixed protocol.
- Crossover washout 14 days.
- Participant blinding uncertain (sensory intensity differed).
- 48h follow-up may not capture full recovery time course.
- Complete recovery not achieved by 48h in young and older adults.

Now I need to write the XML sections.

<THINK_TRACE>: Deep multi-hop derivation & gray-zone audit (>=400 words). This should discuss the causal chain from NHE fatigue → MVC drop → CC intervention → physiological mechanisms (vasoconstriction/vasodilation, compression, lactate clearance, hypoalgesia, stiffness reduction) → recovery outcomes. Also gray zones: T2 is immediate post-session, not pure recovery; blinding uncertainty; sample size underpowered a priori but post hoc overpowered; crossover carryover despite 14-day washout; generalizability limits (elite MMA only at one center); older adults' delayed response and persistent deficit.

<SOURCE_OPERATORS_AND_EQUATIONS>: Formal LaTeX equations, units, page citations, breakdown. I should define the mixed ANOVA model:
Y_{ijkl} = μ + P_i + C_j + T_k + (P×C)_{ij} + (P×T)_{ik} + (C×T)_{jk} + (P×C×T)_{ijk} + S_{l(i)} + ε_{ijkl}
where P=Population, C=Condition, T=Time, S=subject nested in population.
Effect size: Cohen's d_z = (mean difference) / (SD of difference).
Paired t-test: t = \bar{d} / (s_d / √n).
Fatigue index: FI = (MVC_{T0} - MVC_{T1}) / MVC_{T0} × 100%.
Relative recovery: MVC_{T4}/MVC_{T0} × 100%.
Units: MVC in N, stiffness in N/m, perfusion in PU (arbitrary perfusion units), PPT in kPa or N/cm² (note paper uses N/cm² in tables but kPa in methods; 1 N/cm² = 10 kPa), lactate in mmol·L⁻¹, TQR in AU (6-20), Borg CR10 (0-10), temperature in °C, pressure in mmHg, time in min.
Citations: [PAGE 1] abstract, [PAGE 2] methods design, [PAGE 3] intervention, [PAGE 4] fatigue protocol, [PAGE 5] outcomes, [PAGE 6] stats, [PAGE 7] results MVC, [PAGE 8] table 1, [PAGE 9] stiffness/perfusion, [PAGE 10] PPT/lactate/TQR, [PAGE 11] discussion, [PAGE 12] limitations, [PAGE 13-20] supplementary tables, [PAGE 21] sphericity.
Breakdown: breakdown regimes: sphericity violated (Mauchly's W near 0.0005-0.175, p<.001), Greenhouse-Geisser ε applied (0.288-0.666). Singularity: crossover carryover if washout insufficient; blinding breakdown due to sensory difference (3°C/75mmHg vs 15°C/15mmHg).

<RETROCAUSAL_GENEALOGY>: Historical/scientific lineage & multi-week traps. Lineage: Mann & Hagy 1980 (hamstring biomechanics), van der Horst et al. 2015 (NHE prevention), Mjølsnes et al. 2004 (NHE), Allan et al. 2022 (cold history), Roberts et al. 2015 (cold blunting anabolic signaling), Hohenauer et al. 2015 (meta-analysis heterogeneity), Dupuy et al. 2018 (recovery toolbox), Chen et al. 2024 (contrast water therapy), Quesnot et al. 2024 (compression+cryotherapy synergy post-op), Alexander et al. 2022 (elite academy footballers), Trybulski et al. 2024a-d (prior combat sport cryo-compression), Leeder et al. 2012 (CWI meta-analysis), Moore et al. 2023 (CWI systematic review), Martin et al. 2015 (pneumatic compression lactate), Miller et al. 2013 (micro-mobile compression cyclists), Algafly & George 2007 (cryotherapy nerve conduction), Herrera et al. 2010 (cooling nerve conduction), Khoshnevis et al. 2015 (cold-induced vasoconstriction persistence), Hunter et al. 2016 (aging neuromuscular), Li et al. 2024 (age-associated differences in EIMD recovery), Soligard et al. 2016 (load and injury). Multi-week traps: chronic cold exposure around resistance training may blunt hypertrophy/anabolic signaling (Roberts et al., 2015) — trade-off if used chronically; 14-day washout may not eliminate physiological carryover from repeated eccentric damage (EIMD peaks 24-72h but structural repair can take weeks); older adults' motor-unit remodeling (Hunter et al., 2016) reshapes recovery kinetics over weeks, not just 48h.

<RECURSIVE_THEORY_OF_MIND>: Crisis habit regression vs counter-trap vs clock. This is a more abstract section. Crisis habit regression: under fatigue (crisis state), practitioners regress to habitual recovery (ice, rest) rather than evidence-based dosing; counter-trap: assuming CC is universally additive/synergistic when narrative syntheses (Block 2010) show combined cold+compression not directly additive, only marginal gains; clock: the 48h observation window vs biological recovery time course (stiffness peaks 24-96h, Kong et al. 2018), so clock mismatch leads to false conclusion of "recovery" when it's just trajectory improvement. Also participant expectancy/unblinding: participants may guess active condition due to sensory intensity, biasing TQR (subjective). The "counter-trap" is overprescribing CC to older adults assuming same onset as athletes, when data show delayed onset (T3 vs T2) and persistent deficit (69% baseline).

<CROSS_LAYER_VETO_ADJUDICATION>: Physical/biomechanical/weather veto proof. Physical layer: device set at 3°C, but actual skin/intramuscular temperature not measured; thermal gradient means skin ~10-15°C (Belsey et al. 2024 cited), but individual variability in subcutaneous fat, blood flow, limb geometry means actual mechanothermal dose unknown → veto if precise dose required. Biomechanical layer: NHE fatigue induces eccentric damage, stiffness remains above baseline at T4 even under CC (incomplete mechanical normalization); myotonometry only superficial (biceps femoris), no deep muscle/tendon, no shear-wave elastography/MRI → cannot confirm structural recovery. Weather/environmental layer: room temp 20-22°C, RH stable, controlled lab — but real-world application may vary ambient temperature affecting skin cooling rate; high humidity reduces evaporative/convective gradient though device is iceless conductive/convective so less weather-dependent; still, if ambient >22°C, device refrigeration load changes? Not really, it's software-controlled. Veto: outdoor/field application without environmental control introduces uncontrolled thermal boundary conditions.

<RLVR_COUNTERFACTUAL_VETOES>: 3 verifiable RLVR veto scenarios + predictions. RLVR = Reinforcement Learning from Verifiable Rewards? Or some verification framework. I need to create 3 counterfactual veto scenarios that are verifiable (falsifiable). Each scenario: condition, veto rule, prediction.

Scenario 1: Skin temperature measurement veto. If actual mean skin temperature at biceps femoris during CC is not within 10-15°C therapeutic window (per Belsey et al. 2024 cited), then the "3°C set-point" claim is mechanistically unverified. Veto: any conclusion attributing effects specifically to 3°C cooling is void without direct thermometry. Prediction: in a replication with thermocouples, mean skin temp will vary ±3°C across BMI strata (older adults higher subcutaneous fat → warmer skin), explaining delayed onset in older group.

Scenario 2: Carryover/washout veto. If 14-day washout is insufficient for EIMD from NHE (structural repair >14 days in older adults), then crossover contamination biases period 2. Veto: baseline MVC at T0 of period 2 must not differ from period 1 by >5%; if it does, carryover invalidates within-subject contrast. Prediction: older adults will show >5% residual baseline depression in period 2, violating assumption.

Scenario 3: Blinding/sensory veto. If participants can correctly identify CC vs Sham above chance (>60%) due to sensory intensity difference (3°C/75mmHg vs 15°C/15mmHg), then unblinding confounds TQR and Borg. Veto: formal blinding assessment required; without it, subjective outcomes (TQR) are unverifiable. Prediction: a post-session guess questionnaire will show >75% correct identification in MMA athletes (more body-aware), nullifying TQR group differences.

I need to ensure total word count >= 1000 across sections, with THINK_TRACE >= 400 words.

Let me draft carefully, ensuring no betting language. I will not mention odds, spreads, etc.

Let me check page citations:
- Abstract: [PAGE 1]
- Study design, centers, washout, intervention phase: [PAGE 2]
- Eligibility, intervention details (3°C, 75 mmHg, 10 min twice daily, 3 days): [PAGE 3]
- Sham details: [PAGE 3]
- Fidelity, safety: [PAGE 4]
- Fatigue protocol NHE details: [PAGE 4]
- Outcomes: MVC, lactate, perfusion, stiffness, PPT, TQR, Borg: [PAGE 5]
- Sample size, randomization, blinding, stats: [PAGE 6]
- Results flow, baseline characteristics: [PAGE 6]
- Fatigue induction, MVC primary, Table 1: [PAGE 7]
- Table 1 and continued MVC: [PAGE 8]
- Stiffness results: [PAGE 8]
- Perfusion, PPT, lactate, TQR: [PAGE 9]
- Figures, perceived exertion, harms: [PAGE 10]
- Discussion: [PAGE 11]
- Limitations, conclusion: [PAGE 12]
- References: [PAGE 13-14]
- Supplementary tables: [PAGE 15-21]

I will cite these.

Now, word count management. I need >= 1000 words total across XML sections, and THINK_TRACE >= 400 words. Let me make THINK_TRACE about 500-600 words, and others substantial but concise.

I must not invent fake ratios. I can use formal equations from the paper or standard statistical formulas. I should explicitly state assumptions and singularity/breakdown regimes.

Let me write the final output.

Structure:
<THINK_TRACE>
...
</THINK_TRACE>
<SOURCE_OPERATORS_AND_EQUATIONS>
...
</SOURCE_OPERATORS_AND_EQUATIONS>
<RETROCAUSAL_GENEALOGY>
...
</RETROCAUSAL_GENEALOGY>
<RECURSIVE_THEORY_OF_MIND>
...
</RECURSIVE_THEORY_OF_MIND>
<CROSS_LAYER_VETO_ADJUDICATION>
...
</CROSS_LAYER_VETO_ADJUDICATION>
<RLVR_COUNTERFACTUAL_VETOES>
...
</RLVR_COUNTERFACTUAL_VETOES>

I'll make sure to include [PAGE N] markers and verbatim quotes.

Let me draft.

THINK_TRACE (>=400 words):
I'll write about the multi-hop derivation: NHE eccentric load → sarcomere disruption → ↑stiffness, ↓MVC, ↑lactate, ↓perfusion, ↓PPT. CC intervention: cold (3°C) reduces tissue temp, vasoconstriction then reactive hyperemia, ↓nerve conduction velocity → hypoalgesia; compression (75 mmHg intermittent) ↑venous/lymphatic return, ↓interstitial fluid → ↓stiffness, metabolite washout. The 3-way ANOVA partitions variance. Gray zones: T2 is immediate post-session, not recovery per se (authors admit on [PAGE 11]); participant blinding uncertain ([PAGE 6]); a priori n=117 vs achieved n=80 ([PAGE 6]); older adults MVC at T4 only 69.1% baseline under CC vs 46.2% sham — still incomplete recovery ([PAGE 7]); sphericity violated (Mauchly's W near zero), GG ε applied ([PAGE 21]); crossover carryover risk despite 14-day washout ([PAGE 2]); no direct intramuscular temperature/pressure measurement ([PAGE 12]). These gray zones mean the result is "accelerated trajectory" not "full restoration," and generalizability is limited to the exact device/protocol and controlled lab environment.

SOURCE_OPERATORS_AND_EQUATIONS:
Define mixed ANOVA model in LaTeX.
Define Cohen's dz.
Define fatigue index.
Define relative recovery.
Units table.
Breakdown regimes: sphericity (Mauchly's W, p<.001, GG ε 0.288-0.666), blinding breakdown, carryover singularity, dose singularity (no tissue temp/pressure log).
Cite pages.

RETROCAUSAL_GENEALOGY:
Historical lineage with citations from references. Multi-week traps: chronic cold blunting anabolism (Roberts 2015), EIMD repair timeline beyond 48h (stiffness 24-96h Kong 2018), aging motor-unit remodeling (Hunter 2016; Li 2024) meaning older adults need multi-week monitoring not just 48h.

RECURSIVE_THEORY_OF_MIND:
Crisis habit regression: under fatigue, practitioners default to "more cold is better" or passive rest; counter-trap: assuming CC synergy is additive when Block (2010) and narrative syntheses show combined cold+compression not directly additive, only marginal gains; clock: 48h window vs biological recovery, false completion bias. Also expectancy/unblinding.

CROSS_LAYER_VETO_ADJUDICATION:
Physical layer veto: no skin/intramuscular temperature or real-time cuff pressure ([PAGE 12]); Belsey et al. 2024 says skin ~10-15°C but individual gradients unknown. Biomechanical layer: stiffness remains above baseline at T4 even under CC ([PAGE 8]); myotonometry superficial only ([PAGE 5]); no shear-wave elastography/MRI ([PAGE 12]). Weather/environmental layer: controlled 20-22°C, RH stable ([PAGE 2]); field application introduces ambient thermal boundary condition uncertainty; iceless device less weather-dependent but refrigeration performance and skin gradient vary with ambient.

RLVR_COUNTERFACTUAL_VETOES:
3 scenarios with veto rules and predictions.

Let me write it all out now, ensuring word count and strict formatting.

I need to be careful: "ZERO TOY EQUATIONS: Never invent fake ratios (Force / Fatigue)." I will only use formal statistical/physical equations actually appropriate. I won't invent Force/Fatigue ratio.

Also: "State formal LaTeX equations, SI/information/probability units, assumptions, and exact singularity/breakdown regimes."

Let me write.
</NATIVE_REASONING>

<THINK_TRACE>
The causal chain in Trybulski et al. (2026) begins with the Nordic Hamstring Exercise (NHE) fatigue protocol, which imposes high eccentric demand on the knee flexors and produces acute exercise-induced muscle damage (EIMD). At T1, immediately post-fatigue, mean MVC declined by approximately 25.3% in MMA athletes, 30.4% in young adults, and 35.0% in older adults [PAGE 7], confirming a greater relative fatigue burden in the older cohort. This mechanical-metabolic insult elevates hamstring stiffness, reduces microvascular perfusion, lowers pressure pain threshold (PPT), raises blood lactate, and depresses perceived recovery (TQR). The pneumatic cold-compression (CC) intervention (3 °C, nominal peak 75 mmHg intermittent compression, 10 min twice daily for 3 days) is theorized to act through two coupled inputs: (1) thermal extraction reducing tissue temperature and slowing sensory nerve conduction velocity, producing cryo-hypoalgesia and transient vasoconstriction followed by reactive hyperemia; and (2) mechanical compression augmenting venous/lymphatic return and reducing interstitial fluid accumulation, thereby lowering passive stiffness and accelerating metabolite washout [PAGE 3, PAGE 11]. The statistical architecture is a three-way mixed ANOVA with Population as the between-subject factor and Condition × Time as within-subject factors, followed by Bonferroni-adjusted pairwise contrasts and paired Cohen's dz [PAGE 6]. Gray zones cluster around four breakdown regimes. First, T2 is assessed immediately after the first intervention session; the authors explicitly caution that T2 differences may reflect acute physiological responses to cold and compression rather than sustained recovery [PAGE 11], so T2 cannot be interpreted as a 24–48 h recovery endpoint. Second, participant blinding is unverified because active and sham conditions differ in sensory intensity (3 °C/75 mmHg vs 15 °C/15 mmHg), and no formal blinding assessment was performed [PAGE 6], threatening the validity of subjective outcomes such as TQR and Borg CR10. Third, the a priori sample target was n = 117 (dz = 0.30, α = 0.05, 90% power) but enrollment was pragmatically capped at n = 80 with unequal allocation (40 MMA, 20 young, 20 older) [PAGE 6]; although post hoc power exceeded 99% for the observed dz = 1.0 at T4, the reduced and unbalanced sample limits precision for between-population comparisons and renders subgroup findings exploratory. Fourth, sphericity was violated for all repeated measures (Mauchly's W as low as 0.0005–0.175, p < .001), requiring Greenhouse–Geisser corrections with ε ranging from 0.288 to 0.666 [PAGE 21], which signals that the compound symmetry assumption is untenable and the repeated-measures covariance structure is far from spherical. Crossover carryover is another singularity risk: despite a 14-day washout [PAGE 2], eccentric hamstring damage and stiffness can persist beyond 48 h (documented up to 96 h [PAGE 11]), so residual period-1 effects may contaminate period-2 baselines, particularly in older adults whose MVC at T4 under CC remained only 69.1% of baseline versus 46.2% under Sham [PAGE 7]. Finally, the study did not measure individual skin or intramuscular temperatures or real-time cuff pressures at the limb [PAGE 12], meaning the precise mechanothermal dose delivered to tissue is unknown and the findings are best interpreted as effects of a pragmatic device protocol rather than a characterized biophysical dose.
</THINK_TRACE>

<SOURCE_OPERATORS_AND_EQUATIONS>
Formal mixed-effects model for the primary continuous outcome (MVC, stiffness, perfusion, PPT, lactate):

Let \(Y_{ijkl}\) denote the observation for subject \(l\) nested in population \(i\), under condition \(j\), at time \(k\).

\[
Y_{ijkl} = \mu + P_i + C_j + T_k + (P \times C)_{ij} + (P \times T)_{ik} + (C \times T)_{jk} + (P \times C \times T)_{ijk} + S_{l(i)} + \varepsilon_{ijkl}
\]

where \(P \in \{\text{MMA, young, older}\}\), \(C \in \{\text{CC, Sham}\}\), \(T \in \{T_0, T_1, T_2, T_3, T_4\}\), \(S_{l(i)} \sim \mathcal{N}(0, \sigma^2_S)\) is the random subject effect nested in population, and \(\varepsilon_{ijkl} \sim \mathcal{N}(0, \sigma^2_\varepsilon)\) is residual error. Sphericity for repeated factors was assessed via Mauchly's test; when violated (\(p < .001\)), Greenhouse–Geisser corrections were applied with estimated \(\varepsilon \in [0.288, 0.666]\) [PAGE 6, PAGE 21].

Paired within-participant contrast effect size (Cohen's \(d_z\)):

\[
d_z = \frac{\bar{d}}{s_d}, \quad \bar{d} = \frac{1}{n}\sum_{m=1}^{n} (Y_{CC,m} - Y_{Sham,m}), \quad s_d = \sqrt{\frac{1}{n-1}\sum_{m=1}^{n}(d_m - \bar{d})^2}
\]

Paired \(t\)-statistic:

\[
t = \frac{\bar{d}}{s_d / \sqrt{n}} \sim t_{n-1}
\]

Relative fatigue index (RFI) from T0 to T1:

\[
\text{RFI} = \frac{\text{MVC}_{T0} - \text{MVC}_{T1}}{\text{MVC}_{T0}} \times 100\% \; [\%]
\]

Relative MVC recovery at T4:

\[
\text{Recovery}_{T4} = \frac{\text{MVC}_{T4}}{\text{MVC}_{T0}} \times 100\% \; [\%]
\]

SI and information units used in the source:
- MVC: Newtons (N) [PAGE 5]
- Muscle stiffness: Newtons per meter (N/m) [PAGE 5]
- Microvascular perfusion: perfusion units (PU), an arbitrary laser-Doppler flowmetry unit [PAGE 5]
- Pressure pain threshold (PPT): kilopascals (kPa) in methods; tables report N/cm² (1 N/cm² = 10 kPa) [PAGE 5, PAGE 18]
- Blood lactate: millimoles per liter (mmol·L⁻¹) [PAGE 5]
- Temperature: degrees Celsius (°C); CC set-point 3 °C, sham 15 °C [PAGE 3]
- Compression pressure: millimeters of mercury (mmHg); CC high mode nominal peak 75 mmHg, sham 15 mmHg [PAGE 3]
- Exposure duration: minutes (min); 10 min per session, twice daily, 3 days (60 min cumulative) [PAGE 3]
- TQR: arbitrary units (AU), scale 6–20 [PAGE 5]
- Borg CR10: arbitrary units (AU), scale 0–10 [PAGE 5]
- Time: hours (h); T3 = 24 h, T4 = 48 h post-fatigue [PAGE 2]

Breakdown and singularity regimes:
1. Sphericity breakdown: Mauchly's \(W\) values near 0.0005–0.175 with \(p < .001\) across all outcomes [PAGE 21] violate compound symmetry; Greenhouse–Geisser \(\varepsilon\) as low as 0.288 indicates severe departure from sphericity, rendering uncorrected repeated-measures \(F\)-statistics anti-conservative.
2. Blinding breakdown: sensory intensity difference between CC (3 °C, 75 mmHg) and sham (15 °C, 15 mmHg) precludes verified participant blinding [PAGE 6], introducing expectancy bias into ordinal outcomes (TQR, Borg).
3. Dose singularity: no direct measurement of skin temperature, intramuscular temperature, or real-time limb cuff pressure [PAGE 12]; the actual mechanothermal dose at tissue is unquantified, so attribution to the nominal 3 °C/75 mmHg set-point is an assumption, not a measurement.
4. Carryover singularity: 14-day washout may be insufficient for complete resolution of EIMD and stiffness (documented up to 24–96 h [PAGE 11]); period-2 baseline MVC could retain period-1 fatigue residuals, violating crossover independence.
</SOURCE_OPERATORS_AND_EQUATIONS>

<RETROCAUSAL_GENEALOGY>
The study's intellectual lineage traces to foundational hamstring biomechanics and injury etiology: Mann and Hagy (1980) established the hamstrings' role in hip extension, knee flexion, and pelvic control during locomotion [PAGE 1], while van der Horst et al. (2015) provided causal RCT evidence that the Nordic hamstring exercise reduces hamstring injury incidence, justifying its use as an ecologically valid fatiguing stimulus [PAGE 4, PAGE 13]. Mjølsnes et al. (2004) described the canonical NHE technique [PAGE 4]. On the recovery side, Allan et al. (2022) review the historical use of cryotherapies for post-exercise recovery [PAGE 2], and Dupuy et al. (2018) structure the recovery toolbox spanning thermal, mechanical, and active modalities [PAGE 2]. Contemporary syntheses indicate cooling-based strategies can benefit soreness and neuromuscular recovery, whereas contrast water therapy may better target biochemical markers [PAGE 2, citing Chen et al., 2024]. The specific combination of cooling plus compression draws on Quesnot et al. (2024), showing superior functional recovery and symptom control when dynamic compression is added to cryotherapy in postoperative knee cohorts, though narrative syntheses (Block, 2010) caution that combined effects are not directly additive relative to either modality alone [PAGE 2]. Prior work by the same research group in combat-sport athletes (Trybulski et al., 2024a–d) established that 10 min of cryo-compression elicits measurable changes in perfusion, pain threshold, stiffness, and strength, directly informing the 10-min session length selected here [PAGE 3]. Translation to team sport is supported by Alexander et al. (2022), showing acute performance-related improvements in elite academy footballers [PAGE 2]. A critical historical counterweight is Roberts et al. (2015), demonstrating that repeated cold-water immersion can blunt anabolic signaling and satellite-cell responses, implying a trade-off if cryo-compression is used chronically around resistance training [PAGE 2]. Hohenauer et al. (2015) further emphasize heterogeneity in cooling protocols, populations, and endpoints, leaving optimal prescriptions uncertain [PAGE 2].

Multi-week traps embedded in this genealogy: (1) Chronic-use trap — applying CC after every resistance session may attenuate long-term hypertrophic adaptation via blunted anabolic signaling (Roberts et al., 2015), so the acute 3-day benefit does not license indefinite daily use [PAGE 2]. (2) Temporal-compression trap — the study observes only 48 h, yet post-exercise passive stiffness peaks over 24–96 h (Kong et al., 2018 [PAGE 11]); declaring "recovery" at 48 h mistakes trajectory acceleration for completion [PAGE 7, PAGE 11]. (3) Aging trap — older adults exhibit motor-unit remodeling, reduced strength/power, and increased fatigability (Hunter et al., 2016 [PAGE 2]), with age-associated differences in recovery from EIMD (Li et al., 2024 [PAGE 14]); their delayed CC onset (significant at T3 rather than T2 [PAGE 7]) and persistent 48-h deficit (69.1% of baseline under CC [PAGE 7]) imply that a multi-week monitoring window, not a 48-h snapshot, is required to judge true recovery in this stratum.
</RETROCAUSAL_GENEALOGY>

<RECURSIVE_THEORY_OF_MIND>
Crisis habit regression: under the acute stress of post-fatigue testing (T1), clinicians and athletes tend to regress to familiar recovery habits—passive rest, generic icing, or compression—rather than protocol-specified dosing. The data show this regression is only partially rational: stiffness remained above baseline at T4 even under CC (18.0% above baseline in MMA/young, 32.1% in older adults [PAGE 8]), and MVC did not return to baseline in young (76.3%) or older adults (69.1%) [PAGE 7]. Habitual "more is better" application of cold risks the anabolic-blunting trade-off documented chronically (Roberts et al., 2015 [PAGE 2]).

Counter-trap: the opposing error is assuming cryo-compression is inherently synergistic and universally additive. Narrative syntheses explicitly state combined cold plus static compression effects are superior to no intervention but not directly additive relative to either alone, with only marginal gains and substantial heterogeneity (Block, 2010 [PAGE 2]). The present results support a conditional, population-specific benefit: earlier onset in MMA athletes and young adults (T2) versus delayed onset in older adults (T3) [PAGE 7]. Prescribing identical CC dosing and expecting identical timelines across age groups is the counter-trap.

Clock: the observation clock (48 h) is misaligned with the biological recovery clock. Stiffness and soreness from EIMD evolve over 24–96 h [PAGE 11], and lactate clearance under CC was confined to T2 with no between-condition difference at T3 or T4 [PAGE 9]. Thus a 48-h endpoint captures only the early recovery trajectory. Additionally, because participant blinding could not be verified [PAGE 6], expectancy effects may recursively inflate subjective TQR ratings under CC, particularly in body-aware MMA athletes who may more readily detect the active condition's sensory intensity. The recursive loop is: unblinded participants perceive greater benefit → higher TQR → clinician reinforces habit → overprescription beyond the evidence window.
</RECURSIVE_THEORY_OF_MIND>

<CROSS_LAYER_VETO_ADJUDICATION>
Physical layer veto: The device was set to 3 °C with high-mode intermittent compression targeting 75 mmHg, but the authors did not directly measure individual skin or intramuscular temperatures, nor did they log real-time cuff pressures at the limb [PAGE 12]. Because thermal gradients between cuff and tissue are substantial, a 3 °C set-point typically yields skin temperatures near 10–15 °C (Belsey et al., 2024 [PAGE 3]), but individual variation in subcutaneous adiposity (older adults: BMI 26.1 ± 3.2 vs MMA: 23.7 ± 2.6 kg/m² [PAGE 6]) alters the actual tissue dose. Veto: any mechanistic claim that specifically attributes outcomes to a 3 °C intramuscular temperature is invalid without direct thermometry; conclusions must remain at the level of "pragmatic device protocol" effects.

Biomechanical layer veto: Hamstring stiffness was assessed superficially via myotonometry over the biceps femoris [PAGE 5], and the study did not employ shear-wave elastography, MRI, or direct quantification of edema, interstitial fluid shifts, fascial mechanics, or intramuscular hemodynamics [PAGE 12]. Stiffness remained above baseline at T4 under CC in all populations [PAGE 8], so mechanical normalization was incomplete. Veto: claims of structural or deep-tissue recovery are vetoed; the evidence supports only superficial viscoelastic modulation and functional force recovery, not histological or deep-compartment restoration.

Weather/environmental layer veto: Testing occurred under controlled laboratory conditions with room temperature 20–22 °C and stable relative humidity across centers [PAGE 2]. The iceless Med4 Elite unit maintains temperature via internal refrigeration and heat exchange rather than ice [PAGE 3], reducing dependence on ambient ice supply, but the skin-to-ambient thermal boundary condition still governs conductive/convective heat extraction. In uncontrolled field settings with ambient temperature above 22 °C or high humidity, the effective thermal gradient and compressor duty cycle may shift unpredictably. Veto: extrapolation to outdoor or non-climate-controlled sideline applications is vetoed without environmental boundary-condition data; the protocol is validated only within the tested 20–22 °C, stable-humidity envelope.
</CROSS_LAYER_VETO_ADJUDICATION>

<RLVR_COUNTERFACTUAL_VETOES>
Scenario 1 — Skin-temperature dose veto.
Veto rule: If direct thermocouple measurement at the biceps femoris during CC sessions shows mean skin temperature outside the 10–15 °C therapeutic window in >20% of participants (stratified by BMI), then the nominal "3 °C" dosing claim is mechanistically void and all thermal-mechanism inferences are retracted.
Prediction: Older adults (higher subcutaneous fat, BMI 26.1 ± 3.2 [PAGE 6]) will exhibit mean skin temperatures ≥15 °C more frequently than MMA athletes, explaining their delayed CC onset at T3 versus T2 [PAGE 7].

Scenario 2 — Crossover carryover veto.
Veto rule: If baseline MVC (T0) in period 2 differs from baseline MVC in period 1 by more than 5% within any population (paired equivalence test, two one-sided tests, α = 0.05), the washout is insufficient and the within-subject crossover contrast is invalidated for that population.
Prediction: Older adults will show >5% residual baseline depression in period 2 due to slower EIMD resolution (relative fatigue 35.0% vs 25.3% in MMA [PAGE 7]), violating crossover independence and biasing the older-adult CC effect toward the null or away from it depending on period sequence.

Scenario 3 — Unblinding expectancy veto.
Veto rule: If a post-session allocation-guess questionnaire yields correct identification of CC vs Sham above 60% (binomial test against chance 50%, α = 0.05), participant blinding is broken and subjective ordinal outcomes (TQR, Borg CR10) are deemed unverifiable.
Prediction: MMA athletes, with greater interoceptive acuity from combat-sport training, will identify the active condition at >75% accuracy, whereas young and older adults will be nearer chance; consequently, the TQR benefit in MMA at T2–T4 [PAGE 9] should be reweighted as expectancy-contaminated rather than purely physiological.
</RLVR_COUNTERFACTUAL_VETOES>